{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:06:19Z","timestamp":1760234779541,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009057","name":"Associazione Italiana per la Lotta al Neuroblastoma","doi-asserted-by":"publisher","award":["ND"],"award-info":[{"award-number":["ND"]}],"id":[{"id":"10.13039\/100009057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>High-risk neuroblastoma (HR-NB) still remains the most dangerous tumor in early childhood. For this reason, the identification of new therapeutic approaches is of fundamental importance. Recently, we combined the conventional pharmacological approach to NB, represented by cisplatin, with fendiline hydrochloride, an inhibitor of several transporters involved in multidrug resistance of cancer cells, which demonstrated an enhancement of the ability of cisplatin to induce apoptosis. In this work, we co-administrated acetazolamide, a carbonic anhydrase isoform IX (CAIX) inhibitor which was reported to increase chemotherapy efficacy in various cancer types, to the cisplatin\/fendiline approach in SKNBE2 xenografts in NOD-SCID mice with the aim of identifying a novel and more effective treatment. We observed that the combination of the three drugs increases more than twelvefold the differences in the cytotoxic activity of cisplatin alone, leading to a remarkable decrease of the expression of malignancy markers. Our conclusion is that this approach, based on three FDA-approved drugs, may constitute an appropriate improvement of the pharmacological approach to HR-NB.<\/jats:p>","DOI":"10.3390\/ijms22136753","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T11:28:41Z","timestamp":1624447721000},"page":"6753","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-6915","authenticated-orcid":false,"given":"Patrizia","family":"Garbati","sequence":"first","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Barbieri","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9526-1673","authenticated-orcid":false,"given":"Matilde","family":"Calderoni","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-436X","authenticated-orcid":false,"given":"Francesca","family":"Baldini","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Nizzari","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8865-2366","authenticated-orcid":false,"given":"Paola","family":"Modesto","sequence":"additional","affiliation":[{"name":"National Reference Center for Veterinary and Comparative Oncology-Veterinary Medical Research Institute for Piemonte, Liguria and Valle d\u2019Aosta, 10154 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-996X","authenticated-orcid":false,"given":"Tullio","family":"Florio","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"},{"name":"Department of Internal Medicine and Centre of Excellence for Biomedical Research, University of Genova, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-9299","authenticated-orcid":false,"given":"Aldo","family":"Pagano","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"},{"name":"Department of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","article-title":"Recent Advances in Neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/14737140.2017.1285230","article-title":"Overview and recent advances in the treatment of neuroblastoma","volume":"17","author":"Whittle","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drudis.2015.09.017","article-title":"Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds","volume":"21","author":"Thellung","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1158\/1535-7163.MCT-17-0841","article-title":"A high-content screening of anticancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy","volume":"17","author":"Sidarovich","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"18144","DOI":"10.1038\/srep18144","article-title":"Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA","volume":"5","author":"Vella","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Brizzolara, A., Garbati, P., Vella, S., Calderoni, M., Quattrone, A., Tonini, G.P., Capasso, M., Longo, L., Barbieri, R., and Florio, T. (2020). Co-Administration of Fendiline Hydrochloride Enhances Chemotherapeutic Efficacy of Cisplatin in Neuroblastoma Treatment. Molecules, 25.","DOI":"10.3390\/molecules25225234"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1471-4159.2011.07492.x","article-title":"Acquisition of neuron-like electrophysiological properties in neuroblastoma cells by controlled expression of NDM29 ncRNA","volume":"119","author":"Gavazzo","year":"2011","journal-title":"J. Neurochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1096\/fj.10-157032","article-title":"An Alu-like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells","volume":"24","author":"Castelnuovo","year":"2010","journal-title":"FASEB J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Garbati, P., Barbieri, R., Cangelosi, D., Zanon, C., Costa, D., Eva, A., Thellung, S., Calderoni, M., Baldini, F., and Tonini, G.P. (2020). MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment. Biomedicines, 8.","DOI":"10.3390\/biomedicines8110471"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1158\/0008-5472.CAN-03-2224","article-title":"Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion","volume":"64","author":"Robertson","year":"2004","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tips.2006.09.002","article-title":"Targeting tumor-associated carbonic anhydrase IX in cancer therapy","volume":"27","author":"Thiry","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/bjc.1997.201","article-title":"Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan","volume":"75","author":"Vukovic","year":"1997","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjc.6690455","article-title":"Enhancement of chemotherapy by manipulation of tumour pH","volume":"80","author":"Raghunand","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1357-4310(99)01615-9","article-title":"Causes and consequences of tumour acidity and implications for treatment","volume":"6","author":"Stubbs","year":"2000","journal-title":"Mol. Med. Today"},{"key":"ref_16","first-page":"7075","article-title":"Hypoxia-inducible expression of tumor-associated carbonic anhydrases","volume":"60","author":"Wykoff","year":"2000","journal-title":"Cancer Res."},{"key":"ref_17","first-page":"4317","article-title":"Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer","volume":"21","author":"Giatromanolaki","year":"2001","journal-title":"Anticancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.humpath.2011.12.006","article-title":"Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas","volume":"43","author":"Dungwa","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-94-007-7359-2_11","article-title":"Carbonic anhydrase IX: Regulation and role in cancer","volume":"75","author":"Benej","year":"2014","journal-title":"Subcell. Biochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11523-015-0386-5","article-title":"Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN)","volume":"11","author":"Islam","year":"2016","journal-title":"Target. Oncol."},{"key":"ref_21","first-page":"1502","article-title":"Acetazolamide inhibits aquaporin-1 expression and colon cancer xenograft tumor growth","volume":"58","author":"Kong","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1007\/s11033-014-3626-3","article-title":"Stable overexpression of DNA fragmentation factor in T-47D cells: Sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide","volume":"41","author":"Bagheri","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mokhtari, R.B., Kumar, S., Islam, S.S., Yazdanpanah, M., Adeli, K., Cutz, E., and Yeger, H. (2013). Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-378"},{"key":"ref_24","first-page":"404","article-title":"Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma","volume":"31","author":"Ameis","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_25","first-page":"351","article-title":"MCM proteins as diagnostic and prognostic tumor markers in the clinical setting","volume":"25","author":"Giaginis","year":"2010","journal-title":"Histol. Histopathol."},{"key":"ref_26","first-page":"1098","article-title":"Disialoganglioside GD2 on Human Neuroblastoma Cells: Target Antigen for Monoclonal Antibody-mediated Cytolysis and Suppression of Tumor Growth","volume":"47","author":"Mujoo","year":"1987","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.21037\/atm.2019.04.17","article-title":"Reactive astrocytes foster brain metastases via STAT3 signaling","volume":"7","author":"McFarland","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/pr.2011.54","article-title":"Role of stemness-related molecules in neuroblastoma","volume":"71","author":"Kamijo","year":"2012","journal-title":"Pediatr. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1991.9.6.1050","article-title":"Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma","volume":"9","author":"Cheung","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_30","first-page":"65","article-title":"The treatment of neuroblastoma with [131I]MIBG at diagnosis","volume":"39","author":"Troncone","year":"1995","journal-title":"Q. J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1054\/bjoc.2000.1645","article-title":"Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy","volume":"84","author":"Mastrangelo","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/cncr.20648","article-title":"Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma","volume":"101","author":"Kim","year":"2004","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0959-8049(97)00284-0","article-title":"Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma","volume":"33","author":"Norris","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/cddiscovery.2016.82","article-title":"N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics","volume":"2","author":"Casinelli","year":"2016","journal-title":"Cell Death Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3038164","DOI":"10.1155\/2016\/3038164","article-title":"PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs","volume":"2016","author":"Vella","year":"2016","journal-title":"PPAR Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1475-2867-14-59","article-title":"Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA","volume":"14","author":"Costa","year":"2014","journal-title":"Cancer Cell Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0968-0896(00)00288-1","article-title":"Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents?","volume":"9","author":"Supuran","year":"2001","journal-title":"Bioorganic Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Bayat Mokhtari, R., Baluch, N., Ka Hon Tsui, M., Kumar, S., Homayouni, S.T., Aitken, K., Das, B., Baruchel, S., and Yeger, H. (2017). Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3126-7"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002800000262","article-title":"Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells","volume":"48","author":"Jan","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/0960327108097436","article-title":"Fendiline-evoked [Ca2+]i rises and non-Ca2+-triggered cell death in human oral cancer cells","volume":"28","author":"Huang","year":"2009","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/MCB.00884-12","article-title":"Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission","volume":"33","author":"Cho","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"35931","DOI":"10.18632\/oncotarget.5933","article-title":"Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and \u03b2-catenin signaling","volume":"6","author":"Woods","year":"2015","journal-title":"Oncotarget"},{"key":"ref_44","first-page":"9299","article-title":"Combined treatment with acetazolamide and cisplatin enhances chemosensitivity in laryngeal carcinoma Hep-2 cells","volume":"15","author":"Gao","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1158\/1535-7163.MCT-06-0145","article-title":"Chronic hypoxia promotes hypoxia-inducible factor-1-\u03b1-dependent resistance to etoposide and vincristine in neuroblastoma cells","volume":"5","author":"Hussein","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/bcr2615","article-title":"ImmunoRatio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67","volume":"12","author":"Tuominen","year":"2010","journal-title":"Breast Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6753\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:22:19Z","timestamp":1760163739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":47,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22136753"],"URL":"https:\/\/doi.org\/10.3390\/ijms22136753","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,6,23]]}}}